NRX Pharmaceuticals (NRXP) Operating Margin (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly Operating Margin came in at 444.01% in Q1 2026, up 8.01% on a QoQ basis from 482.67% in Q4 2025.

NRX Pharmaceuticals (NRXP) Operating Margin (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 2 years of Operating Margin data on file, last reported at 444.01% in Q1 2026.

On a quarterly basis, Operating Margin changed N/A year-over-year to 444.01% in Q1 2026; TTM through Mar 2026 was 769.09%, a N/A change from a year earlier, with the FY2025 full-year figure at 1352.0%, changed N/A from the prior year.
Operating Margin for Q1 2026 stood at 444.01%, up from 482.67% in the prior quarter.
Over the last five years, Operating Margin for NRXP reached as high as 444.01% in Q1 2026 and fell as low as 2012.0% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Oculis Holding AG	67,102.16 Bn	67,101.87 Bn	-	-
2	Nanobiotix	1,913.50 Bn	1,913.44 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	-
4	BeOne Medicines	473.74 Bn	468.95 Bn	1.35 Bn	16.51%
5	Vertex Pharmaceuticals	122.07 Bn	114.82 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	70.00 Bn	61.24 Bn	3.31 Bn	17.83%
7	Belite Bio	62.34 Bn	62.34 Bn	-	-
8	Argenx Se	55.96 Bn	50.77 Bn	1.41 Bn	31.68%
9	Alnylam Pharmaceuticals	37.49 Bn	34.48 Bn	959.66 Mn	23.02%
10	NRX Pharmaceuticals	117.34 Mn	110.64 Mn	437,000.00	-444.01%

Download Data